News Home

Should You Buy Harmony Biosciences Holdings Inc (HRMY) Stock on Tuesday?

Tuesday, February 27, 2024 12:00 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Harmony Biosciences Holdings Inc (HRMY) Stock on Tuesday?

The market has been neutral on Harmony Biosciences Holdings Inc (HRMY) stock recently. HRMY gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,neutral
Harmony Biosciences Holdings Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on HRMY!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With HRMY Stock Today?

Harmony Biosciences Holdings Inc (HRMY) stock has risen 1.79% while the S&P 500 is lower by -0.02% as of 11:43 AM on Tuesday, Feb 27. HRMY is up $0.58 from the previous closing price of $32.47 on volume of 99,498 shares. Over the past year the S&P 500 is higher by 27.27% while HRMY is lower by -26.16%. HRMY earned $2.13 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 15.44. To see InvestorsObserver's Sentiment Score for Harmony Biosciences Holdings Inc click here.

More About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The companys product WAKIX pitolisant is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. Click Here to get the full Stock Report for Harmony Biosciences Holdings Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App